Overview

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
Seven and Eight Biopharmaceuticals Inc
Treatments:
Pembrolizumab